Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12226479 | 1.00 | GAA (0.56) | GAAALDH1A1HTTSMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL2672515 | 0.97 | ALDH1A1 (0.59) | GAAALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL514070 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL5552935 | 0.95 | ALDH1A1 (0.55) | GAAALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL1908554 | 0.92 | — | — | |
| SCHEMBL8060957 | 0.86 | NPSR1 (0.46) | GAAALDH1A1HTTSMN1; SMN2TDP1 | |
| SCHEMBL12909322 | 0.86 | — | — | |
| SCHEMBL13165521 | 0.86 | NPSR1 (0.46) | GAAALDH1A1HTTSMN1; SMN2TDP1 | |
| SCHEMBL13527664 | 0.86 | NPSR1 (0.46) | GAAALDH1A1HTTSMN1; SMN2TDP1 | |
| SCHEMBL22815172 | 0.81 | HSD17B10 (0.47) | GAAALDH1A1HTTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069321-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | Digital Biotech Co., Ltd. (KR) | 2009-06-17 | — | — | EP | claimed |
| WO-2008041826-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2008-04-10 | — | — | WO | claimed |
| WO-2023247593-A1 | PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023250513-A1 | 13-MEMBERED MACROLIDE COMPOUNDS FOR TREATING DISEASES MEDIATED BY ABNORMAL PROTEIN TRANSLATION | ZIKANI THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
| US-11185514-B2 | Aqueous solution comprising a polyphenol | OPTERION HEALTH AG (CH) | 2021-11-30 | — | — | US | disclosed |
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| US-11026936-B2 | Piperidinyl-propanone derivatives | MERCK PATENT GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| US-11026936-B2 | Piperidinyl-propanone derivatives | MERCK PATENT GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| CN-108779093-B | N1- (3,3, 3-trifluoro-2-hydroxy-2-methylpropionyl) -piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase | 默克专利股份公司 | 2021-03-09 | — | — | CN | disclosed |
| WO-2020207260-A1 | CDK INHIBITOR AND APPLICATION THEREOF | 珠海宇繁生物科技有限责任公司 | 2020-10-15 | — | — | WO | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. | 2007-05-03 | — | — | US | disclosed |
| US-7208495-B2 | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005004865-A1 | USE OF 5-HT4(A)-SEROTONIN RECEPTOR AGONISTS | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN (DE) | 2005-01-20 | — | — | WO | disclosed |
| EP-0068866-B1 | METHOD OF MANUFACTURING ACETONE OR METHYL ETHYL KETONE | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1985-07-24 | — | — | EP | disclosed |
| US-4481373-A | CATALYTIC OXIDATION OF OLEFINS IN PRESENCE OF TERTIARY AMINE OF AMIDE | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1984-11-06 | — | — | US | disclosed |
| EP-0068866-A1 | Method of manufacturing acetone or methyl ethyl ketone | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026936-B2 | Piperidinyl-propanone derivatives | PDK2, PDK3, PDK1 | GAA 1192/4885ALDH1A1 115/4885HTT 2169/4885 |
| US-11185514-B2 | Aqueous solution comprising a polyphenol | SORD, SI, AQP1 | GAA 363/4885ALDH1A1 602/4885HTT 374/4885 |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | GAA 16/4885ALDH1A1 1111/4885HTT 533/4885 |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | SCN1B, CACNA1B, SCN2A | GAA 4181/4885ALDH1A1 2549/4885HTT 754/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | GAA 3099/4885ALDH1A1 2843/4885HTT 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.